Anchor, Ortho-McNeil-Janssen to Collaborate on Peptide Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The J&J subsidiary will pay an undisclosed amount to license drugs on fewer than 10 targets in cancer and metabolic disorders.